Skip to content
lifestyle.d-h.st
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Gan & Lee Pharmaceuticals
A New Paradigm for Long-Term Weight Management: Once-Monthly Bofanglutide Maintenance Therapy Delivers Positive Results in Weight Control and Maintenance Over 24 Weeks — Gan & Lee Pharmaceuticals’ GRADUAL-3 Study Meets Its Primary Endpoint
November 4, 2026
First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA
September 9, 2026
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases — Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
June 12, 2026